ÂÜÀòÂÒÂ×

Xiaojing Yang began their work experience in 2005 as an Exchange Ph.D student at the Genome Institute of Singapore. In 2009, they moved to the University of Southern California as a Postdoctoral Research Associate where they tested and analyzed global effects of combinatorial treatments, screened panels of potential DNA demethylation agents, elucidated the function of H2A.Z in 5-Aza-2'-deoxycytine (Decitabine) induced gene reactivation process, developed a novel prognostic marker for AML patients, developed new non-invasive biomarkers for monitoring patients' responses to demethylation drugs, developed a novel assay to detect global chromatin architecture, investigated epigenetic signatures of genes with non-CpG island promoters, and identified the driver epigenetic events of cancer cell survival. In 2015, Xiaojing Yang joined Zymo Research Corp as a Scientist where they developed and commercialized a DNA methylation based bladder cancer monitor test, developed a single tube highly multiplex target enrichment platform, and developed and commercialized a direct-to-consumer test based on the platform.

Xiaojing Yang attended the middle school attached to Northwestern Polytechnical University from an unknown start year to an unknown end year. xiaojing then attended Peking University from 1999 to 2003, where they earned a Bachelor's degree in Pharmaceutical Sciences. Finally, they attended Tsinghua University from 2003 to 2008, where they earned a Ph.D in Pharmacology.